AU2016221627A1 - Pharmaceutical formulations of C1 esterase inhibitor - Google Patents

Pharmaceutical formulations of C1 esterase inhibitor Download PDF

Info

Publication number
AU2016221627A1
AU2016221627A1 AU2016221627A AU2016221627A AU2016221627A1 AU 2016221627 A1 AU2016221627 A1 AU 2016221627A1 AU 2016221627 A AU2016221627 A AU 2016221627A AU 2016221627 A AU2016221627 A AU 2016221627A AU 2016221627 A1 AU2016221627 A1 AU 2016221627A1
Authority
AU
Australia
Prior art keywords
inh
mosm
pharmaceutical formulation
formulation
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016221627A
Other languages
English (en)
Inventor
Ernst-Juergen Kanzy
Frauke May
Hubert Metzner
Ingo Pragst
Wolfram Schaefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of AU2016221627A1 publication Critical patent/AU2016221627A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016221627A 2015-02-20 2016-02-19 Pharmaceutical formulations of C1 esterase inhibitor Abandoned AU2016221627A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15156010 2015-02-20
EP15156010.9 2015-02-20
PCT/EP2016/053559 WO2016131958A1 (en) 2015-02-20 2016-02-19 Pharmaceutical formulations of c1 esterase inhibitor

Publications (1)

Publication Number Publication Date
AU2016221627A1 true AU2016221627A1 (en) 2017-08-17

Family

ID=52573617

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016221627A Abandoned AU2016221627A1 (en) 2015-02-20 2016-02-19 Pharmaceutical formulations of C1 esterase inhibitor

Country Status (13)

Country Link
US (1) US20180036394A1 (enExample)
EP (1) EP3258911A1 (enExample)
JP (1) JP6516855B2 (enExample)
KR (1) KR20170118856A (enExample)
CN (1) CN107257683A (enExample)
AU (1) AU2016221627A1 (enExample)
BR (1) BR112017017685A2 (enExample)
CA (1) CA2977090A1 (enExample)
IL (1) IL253824A0 (enExample)
MX (1) MX2017010323A (enExample)
RU (1) RU2017132449A (enExample)
SG (1) SG11201706019XA (enExample)
WO (1) WO2016131958A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
CN120381522B (zh) * 2025-04-02 2026-01-23 南方医科大学南方医院 一种治疗肝硬化门脉高压的化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012311483B2 (en) * 2011-09-24 2016-03-10 Csl Behring Gmbh Combination therapy using immunoglobulin and C1-inhibitor
ME03326B (me) * 2013-03-15 2019-10-20 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze

Also Published As

Publication number Publication date
JP2018509398A (ja) 2018-04-05
MX2017010323A (es) 2017-12-07
IL253824A0 (en) 2017-09-28
US20180036394A1 (en) 2018-02-08
SG11201706019XA (en) 2017-09-28
CN107257683A (zh) 2017-10-17
EP3258911A1 (en) 2017-12-27
BR112017017685A2 (pt) 2018-04-10
RU2017132449A (ru) 2019-03-21
CA2977090A1 (en) 2016-08-25
KR20170118856A (ko) 2017-10-25
JP6516855B2 (ja) 2019-05-22
WO2016131958A1 (en) 2016-08-25
RU2017132449A3 (enExample) 2019-09-05

Similar Documents

Publication Publication Date Title
JP7150804B2 (ja) プラミノーゲンを含む医薬組成物及びその使用
KR102579789B1 (ko) C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
JP2006257099A (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
TW201733609A (zh) 補體活性之調節劑
US20180036394A1 (en) Pharmaceutical formulations of c1 esterase inhibitor
WO2015095925A1 (en) Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof
US11554156B2 (en) Pharmaceutical formulations of C1 esterase inhibitor
JP7522033B2 (ja) グルコセレブロシダーゼ及びイソファゴミンを含む製剤
JP2025072464A (ja) 改善された凍結乾燥製剤
BR112017012972B1 (pt) Composição farmacêutica que compreende plasminogênio e seus usos
HK1236840A1 (en) Pharmaceutical composition comprising plasminogen and uses thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period